Market Overview:
The global diabetic neuropathy drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising geriatric population, and technological advancements in the field of diabetic neuropathy drugs. Based on type, the global diabetic neuropathy drugs market is segmented into calcium channel alpha-2 delta ligand, SNRIs and TCAs, and others. The calcium channel alpha-2 delta ligand segment is expected to grow at a CAGR of 6.1% during the forecast period from 2018 to 2030 due to its high efficacy in treating various symptoms associated with diabetic neuropathy such as pain and numbness. Based on application, the global diabetic neuropathy drugs market is segmented into hospitals, drug stores, and others (clinics/physicians’ offices). The hospitals segment accounted for majority share (64%) of the global diabetic neuropathy drugs market in 2017 owing to increasing number of hospital admissions for treatment of diabetes-related complications such as foot ulcers and nerve damage.
Product Definition:
There are many different types of diabetic neuropathy. The most common type is peripheral neuropathy, which affects the nerves in your feet and legs. This type of diabetic neuropathy can cause pain, tingling, numbness, and weakness in your feet and legs. It can also make it difficult to walk or stand for long periods of time. Autonomic neuropathy affects the nerves that control your body's automatic functions, such as heart rate, blood pressure, and digestion. This type of diabetic neuropathy can cause problems with bladder control, sexual function, sweating ,and stomach problems . Other types of diabetic neuropathies include mononeuropathies (nerve damage in a single nerve), optic nerve damage (vision loss), and polyneuropathies (multiple nerves are affected).
Calcium Channel Alpha-2 Delta Ligand:
Calcium channel alpha-2 Delta ligand is a protein that modifies the conductance of calcium channels. It is also known as CCK-2 or CACNG1. The ligand binding to its receptor on the membrane increases the conductance of calcium channels and allows them to open more easily, which results in increased influx of sodium ions into cells and cell depolarization.
SNRIs and TCAs:
Solution Nucleoside reverse transcriptase inhibitors (SNRIs) and tricyclic antidepressants (TCAs) are used for treatment of diabetic neuropathy. SNRIs and TCA are also used in the management of post-acute pain associated with diabetic peripheral vascular disease. Neuropathic pain is caused by damage to nerves that supply the brain, spinal cord, and nerve roots; it can occur as a result of diabetes or other disorders such as multiple sclerosis or stroke.
Application Insights:
Based on application, the global market is segmented into hospitals, pharmacies and drug stores, and others. Hospitals held the largest share in 2017 owing to availability of advanced healthcare facilities for patients with diabetes. Moreover, presence of a large patient base with neuropathy-related complications in hospitals further boosts product demand.
Pharmacies are expected to be the fastest-growing application segment over the forecast period due to increasing awareness about treatment options among consumers as well as healthcare professionals. Increasing number of retail outlets selling medicines has also positively influenced product demand at these locations. For instance, CVS Health Corporation operates more than 10,000 pharmacy locations across all 50 U.S states and territories which offer a wide range of products including diabetic neuropathy drugs under one roof thus driving its revenue growth over the forecast period through 2030 ¢â‚¬Å“ Prescription Drug Stores (PDS).
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of diabetes are some factors responsible for its growth. According to the American Diabetes Association, around 29 million people were diagnosed with diabetes in 2015 and it is estimated that by 2035 this number will reach 42 million. In addition, an increase in awareness about neuropathy treatment options is also expected to boost regional demand during the forecast period.
Asia Pacific region is anticipated to witness lucrative CAGR over the forecast period owing to rising healthcare expenditure by governments as well as private organizations along with increasing patient awareness levels regarding available treatment options for diabetic peripheral neuropathy symptoms & signs’s management & prevention methods such as regular check-ups by doctors or podiatrists especially when they are at risk of developing into more severe forms such as amputations or foot ulcers which require surgical intervention at a later stage thus resulting into higher medical costs associated with treating these infections/ulcers etc.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is expected to drive the demand for diabetic neuropathy drugs in the coming years.
- Growing awareness about diabetic neuropathy: There is a growing awareness among people about the symptoms and treatment options for diabetic neuropathy. This is likely to boost the demand for diabetic neuropathy drugs in the near future.
- Rising incidence of nerve injuries: The incidence of nerve injuries is on the rise due to increasing number of accidents and surgeries. This will create a positive outlook for the growth of Diabetic Neuropathy Drugs market in forthcoming years .
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Neuropathy Drugs Market Research Report
By Type
Calcium Channel Alpha-2 Delta Ligand, SNRIs and TCAs, Others
By Application
Hospitals, Drug Stores, Others
By Companies
Pfizer, Novartis, Johnson & Johnson, Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceutical, Daiichi Sankyo, Astellas Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
132
Number of Tables & Figures
93
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Neuropathy Drugs Market Report Segments:
The global Diabetic Neuropathy Drugs market is segmented on the basis of:
Types
Calcium Channel Alpha-2 Delta Ligand, SNRIs and TCAs, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Drug Stores, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Johnson & Johnson
- Eli Lilly
- GlaxoSmithKline
- Boehringer Ingelheim
- Teva Pharmaceutical
- Daiichi Sankyo
- Astellas Pharma
Highlights of The Diabetic Neuropathy Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Calcium Channel Alpha-2 Delta Ligand
- SNRIs and TCAs
- Others
- By Application:
- Hospitals
- Drug Stores
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Neuropathy Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetic neuropathy drugs are medications that help to improve the symptoms of diabetic neuropathy. These medications can help to reduce the pain and inflammation that is associated with this condition, as well as improve blood flow and nerve function.
Some of the major companies in the diabetic neuropathy drugs market are Pfizer, Novartis, Johnson & Johnson, Eli Lilly, GlaxoSmithKline, Boehringer Ingelheim, Teva Pharmaceutical, Daiichi Sankyo, Astellas Pharma.
The diabetic neuropathy drugs market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Diabetic Neuropathy Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Diabetic Neuropathy Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Diabetic Neuropathy Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Diabetic Neuropathy Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Diabetic Neuropathy Drugs Market Size & Forecast, 2018-2028
4.5.1 Diabetic Neuropathy Drugs Market Size and Y-o-Y Growth
4.5.2 Diabetic Neuropathy Drugs Market Absolute $ Opportunity
Chapter 5 Global Diabetic Neuropathy Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Diabetic Neuropathy Drugs Market Size Forecast by Type
5.2.1 Calcium Channel Alpha-2 Delta Ligand
5.2.2 SNRIs and TCAs
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Diabetic Neuropathy Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Diabetic Neuropathy Drugs Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Drug Stores
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Diabetic Neuropathy Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Diabetic Neuropathy Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Diabetic Neuropathy Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Diabetic Neuropathy Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Diabetic Neuropathy Drugs Market Size Forecast by Type
9.6.1 Calcium Channel Alpha-2 Delta Ligand
9.6.2 SNRIs and TCAs
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Diabetic Neuropathy Drugs Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Drug Stores
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Diabetic Neuropathy Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Diabetic Neuropathy Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Diabetic Neuropathy Drugs Market Size Forecast by Type
10.6.1 Calcium Channel Alpha-2 Delta Ligand
10.6.2 SNRIs and TCAs
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Diabetic Neuropathy Drugs Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Drug Stores
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Diabetic Neuropathy Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Diabetic Neuropathy Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Diabetic Neuropathy Drugs Market Size Forecast by Type
11.6.1 Calcium Channel Alpha-2 Delta Ligand
11.6.2 SNRIs and TCAs
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Diabetic Neuropathy Drugs Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Drug Stores
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Diabetic Neuropathy Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Diabetic Neuropathy Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Diabetic Neuropathy Drugs Market Size Forecast by Type
12.6.1 Calcium Channel Alpha-2 Delta Ligand
12.6.2 SNRIs and TCAs
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Diabetic Neuropathy Drugs Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Drug Stores
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Diabetic Neuropathy Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Diabetic Neuropathy Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Diabetic Neuropathy Drugs Market Size Forecast by Type
13.6.1 Calcium Channel Alpha-2 Delta Ligand
13.6.2 SNRIs and TCAs
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Diabetic Neuropathy Drugs Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Drug Stores
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Diabetic Neuropathy Drugs Market: Competitive Dashboard
14.2 Global Diabetic Neuropathy Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Johnson & Johnson
14.3.4 Eli Lilly
14.3.5 GlaxoSmithKline
14.3.6 Boehringer Ingelheim
14.3.7 Teva Pharmaceutical
14.3.8 Daiichi Sankyo
14.3.9 Astellas Pharma
